1838 related articles for article (PubMed ID: 23063375)
1. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
2. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
[TBL] [Abstract][Full Text] [Related]
3. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.
Eltink C; Lee J; Schaddelee M; Zhang W; Kerbusch V; Meijer J; van Marle S; Grunenberg N; Kowalski D; Drogendijk T; Moy S; Iitsuka H; van Gelderen M; Matsushima H; Sawamoto T
Int J Clin Pharmacol Ther; 2012 Nov; 50(11):838-50. PubMed ID: 22943933
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies.
Iitsuka H; Tokuno T; Amada Y; Matsushima H; Katashima M; Sawamoto T; Takusagawa S; van Gelderen M; Tanaka T; Miyahara H
Clin Drug Investig; 2014 Jan; 34(1):27-35. PubMed ID: 24178236
[TBL] [Abstract][Full Text] [Related]
5. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
6. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
[TBL] [Abstract][Full Text] [Related]
7. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects.
Iitsuka H; van Gelderen M; Katashima M; Takusagawa S; Sawamoto T
Clin Ther; 2015 May; 37(5):1031-44. PubMed ID: 25791612
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
13. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
14. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study.
Lee S; Gu N; Kim BH; Lim KS; Shin SG; Jang IJ; Yu KS
Clin Ther; 2012 May; 34(5):1160-9. PubMed ID: 22503212
[TBL] [Abstract][Full Text] [Related]
16. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.
Spínola AC; Almeida S; Filipe A; Neves R; Trabelsi F; Farré A
Clin Ther; 2009 Sep; 31(9):1992-2001. PubMed ID: 19843489
[TBL] [Abstract][Full Text] [Related]
17. Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly men.
van Gelderen M; Tretter R; Meijer J; Dorrepaal C; Gangaram-Panday S; Brooks A; Krauwinkel W; Dickinson J
Int J Clin Pharmacol Ther; 2014 Aug; 52(8):693-701. PubMed ID: 24755125
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.
Nunes T; Rocha JF; Vaz-da-Silva M; Falcão A; Almeida L; Soares-da-Silva P
Clin Ther; 2011 Jun; 33(6):776-91. PubMed ID: 21704242
[TBL] [Abstract][Full Text] [Related]
19. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
Lee J; Moy S; Meijer J; Krauwinkel W; Sawamoto T; Kerbusch V; Kowalski D; Roy M; Marion A; Takusagawa S; van Gelderen M; Keirns J
Clin Drug Investig; 2013 Jun; 33(6):429-40. PubMed ID: 23625188
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies.
Kim TE; Gu N; Yoon SH; Cho JY; Park KM; Shin SG; Jang IJ; Yu KS
Clin Ther; 2012 Feb; 34(2):482-94. PubMed ID: 22284902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
